NCT lookup

Inclusion Criteria:

1. Adult and adolescent patients (age ≥12 years) at the Index Date (i.e., first administration of tezepelumab);
2. Patients with severe uncontrolled asthma (diagnosed according to clinician's judgment as per ERS-ATS or GINA guidelines) requiring a stable treatment of high doses of ICS and a long acting β2 agonist ± additional asthma controller;
3. Patients who received at least one injection of tezepelumab from February 2024 to March 2025 , according to Italian reimbursement indications;
4. Patients who signed the ICF and privacy form.
5. Patients with continuous enrolment in the data source for at least 12-months before the index date.
6. Patients with at least three months of continuous enrolment in the data source after the index date.

Exclusion Criteria:

1. Patients with hypersensitivity to the active ingredient or any of the excipients of Tezspire;
2. Patients who received any biologic drug for the treatment of asthma in a clinical trial at any time during the 12-months prior to the index date.
3. Patients who, during the observation period, participated in studies imposing a specific patient's management strategy, which does not correspond to the site's normal clinical practice.

• Cittadella (PD), Padova, Italy
• Montebelluna (TV), TV, Italy
• Aosta, Italy
• Avellino, Italy
• Bari, Italy
• Bergamo, Italy
• Brescia, Italy
• Cagliari, Italy
• Catania, Italy
• Catanzaro, Italy
• Civitanova Marche, Italy
• Ferrara, Italy
• Foggia, Italy
• Garbagnate(MI), Italy
• Genova, Italy
• Lamezia Terme, Italy
• Massa Carrara, Italy
• Milan, Italy
• Modena, Italy
• Naples, Italy
• Orbassano (TO), Italy
• Padova, Italy
• Reggio Emilia, Italy
• Roma, Italy
• Sassari, Italy
• Torino, Italy
• Tradate (VA), Italy
• Verona, Italy